Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer
Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate
Sponsor: Burzynski Research Institute
Terminated
Slow accrual
Other terminated trials from Burzynski Research Institute
Other Metastatic Prostate Cancer trials with similar outcome
Listed as NCT00003533, this PHASE2 trial focuses on Metastatic Prostate Cancer and remains terminated or withdrawn. Sponsored by Burzynski Research Institute, it has been updated 6 times since 1996, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
▶ Show 1 earlier version
-
Jan 2017 — Dec 2017 [monthly]
Unknown Status PHASE2
First recorded
Feb 1996
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Burzynski Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .